SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (2141)8/22/1997 6:44:00 PM
From: biowa   of 9719
 
V1,

>>VRTX is well behind GLFD<<

Actually, I would guess the lead is somewhere around 6-12 months. My impression is that VRTX expects to enter the clinic sometime in 1998; in fact the WSJ today quotes the company on this: "It says that its drugs have also successfully restored injured nerves in laboratory animals, and that human trials of its medicines could begin in a year or so." (p. B14) The Guilford website estimates a end of 1997 or early 1998 beginning for clinical trials. (http://www.guilfordpharm.com/products/neurotrp.htm)

Anyway, my primary point in citing VRTX was that much of the coverage had protrayed this as if AMGN had acquired a totally unique group of candidates. As for who reaches approval first, AMGN has been amazing lately in the speed with which they bring candidates through clinicals.

BTW, Andy- Sorry if you misread that as a direct quote of you; I intended that as an amalgam of some of the things I've heard and read. When I want to misquote you personally, I'll make sure to make the proper bibliographic citation ;-).

IMO, what we really need to change the way biotech is valued is either (a) more products actually making it through approval, or (b) another acquisition (of whole biotechs) spree by pharmas.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News